Tag: NCT03438396

Home / NCT03438396

Categories

Tisotumab forvedotin-tftv is approved for recurrent or metastatic cervical cancer

October 2021: The FDA has given tisotumab vedotin-tftv (Tivdak, Seagen Inc.), a tissue factor-directed antibody and microtubule inhibitor combination, rapid approval for adult patients with recurrent ...
nct03438396

Scan the code